Key Highlights

  • Avere Therapeutics' reverse merger with NextCure is backed by a $320 million private placement led by Fairmount and Hansoh Pharma.
  • The financing extends the combined company's operational runway through a Phase 2b psoriasis readout expected in early 2028.
  • Proceeds will also support the launch of a separate Phase 2b trial evaluating AVR-001 in ulcerative colitis.
  • Hansoh Pharma's dual role as both licensor of AVR-001 and a lead investor in the financing underscores strong alignment of interest in the combined company's success.

Avere Therapeutics (NASDAQ: AVRX) has secured a substantial $320 million private placement, led by investment firm Fairmount and Hansoh Pharma, providing the newly public company with a multi-year capital runway to advance its pipeline following its reverse merger with NextCure. The scale of this financing is a central reason the combined transaction has been viewed as a genuine capital infusion rather than a purely structural reorganization.

Private placements of this size are relatively uncommon for early clinical-stage biotech companies, and the involvement of Hansoh Pharma as a lead investor carries particular significance given that Hansoh is also the company that originally licensed AVR-001, Avere's lead drug candidate, to the business. This dual role as both licensor and financier suggests Hansoh has direct insight into AVR-001's underlying science and is putting meaningful capital behind its own assessment of the molecule's potential.

The proceeds from this financing are earmarked to fund the combined company through two major near-to-medium-term clinical catalysts: a Phase 2b psoriasis readout for AVR-001 expected in early 2028, and the launch of a separate Phase 2b trial evaluating the same molecule in ulcerative colitis. Having capital secured through both of these mid-stage clinical milestones gives Avere meaningful visibility into its development pathway without needing to return to capital markets in the near term.

For clinical-stage biotech companies, securing adequate funding through key value-inflection points is often the difference between a promising drug candidate reaching later-stage development and one that stalls for lack of resources. This financing structure appears designed specifically to remove that risk for AVR-001's ongoing psoriasis and forthcoming ulcerative colitis programs.

The financing also reflects a broader capital markets trend in which private biotech companies increasingly use reverse mergers combined with substantial concurrent private placements to access public markets efficiently, bypassing the more traditional and often slower IPO process while still securing the capital needed to fund clinical development.

With this funding now in place, investor attention is likely to shift toward Avere's execution on its clinical timeline, with the 2028 Phase 2b psoriasis readout standing as the most significant near-to-medium-term catalyst that will determine how successfully the company converts this capital into demonstrated clinical value.